Business Wire1mon
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple ...
Nature25d
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells in vitro, but its physiological role in tumor surveillance remains unknown. Here ...
Medscape18y
TNF-alpha Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study
Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...
Medscape27d
Anti-TNF-α Agents in the Treatment of Immune-mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls
55 11 3061 7457 Fax: +55 11 3081 7190 [email protected] Establishing that TNF-α plays an important role in the pathogenesis of several immune-mediated inflammatory diseases led to the development of ...
Nature16d
Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule
and TNF-related apoptosis-inducing ligand (TRAIL). In contrast to its role in nuclear factor κB activation, RIP requires its own kinase activity for death signaling. Thus, Fas, TRAIL and TNF ...